nodes	percent_of_prediction	percent_of_DWPC	metapath
Lithium—GSK3A—penis—type 2 diabetes mellitus	0.0363	0.162	CbGeAlD
Lithium—GRIA3—nerve—type 2 diabetes mellitus	0.0221	0.0988	CbGeAlD
Lithium—GSK3B—nerve—type 2 diabetes mellitus	0.0192	0.0856	CbGeAlD
Lithium—IMPA2—islet of Langerhans—type 2 diabetes mellitus	0.00946	0.0423	CbGeAlD
Lithium—IMPA1—cardiovascular system—type 2 diabetes mellitus	0.00912	0.0407	CbGeAlD
Lithium—IMPA1—kidney—type 2 diabetes mellitus	0.00892	0.0398	CbGeAlD
Lithium—GSK3A—islet of Langerhans—type 2 diabetes mellitus	0.00807	0.036	CbGeAlD
Lithium—IMPA2—nephron tubule—type 2 diabetes mellitus	0.00762	0.034	CbGeAlD
Lithium—GSK3A—retina—type 2 diabetes mellitus	0.0069	0.0308	CbGeAlD
Lithium—GSK3B—cardiovascular system—type 2 diabetes mellitus	0.00671	0.03	CbGeAlD
Lithium—IMPA2—kidney—type 2 diabetes mellitus	0.00669	0.0299	CbGeAlD
Lithium—IMPA2—pancreas—type 2 diabetes mellitus	0.00665	0.0297	CbGeAlD
Lithium—GSK3B—kidney—type 2 diabetes mellitus	0.00657	0.0293	CbGeAlD
Lithium—IMPA2—cortex of kidney—type 2 diabetes mellitus	0.00652	0.0291	CbGeAlD
Lithium—GSK3A—nephron tubule—type 2 diabetes mellitus	0.0065	0.029	CbGeAlD
Lithium—IMPA2—adipose tissue—type 2 diabetes mellitus	0.00603	0.0269	CbGeAlD
Lithium—GSK3B—adipose tissue—type 2 diabetes mellitus	0.00592	0.0264	CbGeAlD
Lithium—GSK3A—cardiovascular system—type 2 diabetes mellitus	0.00584	0.0261	CbGeAlD
Lithium—GSK3A—pancreas—type 2 diabetes mellitus	0.00567	0.0253	CbGeAlD
Lithium—IMPA1—liver—type 2 diabetes mellitus	0.00564	0.0252	CbGeAlD
Lithium—GSK3A—cortex of kidney—type 2 diabetes mellitus	0.00556	0.0248	CbGeAlD
Lithium—GSK3A—adipose tissue—type 2 diabetes mellitus	0.00515	0.023	CbGeAlD
Lithium—GRIA3—liver—type 2 diabetes mellitus	0.00479	0.0214	CbGeAlD
Lithium—IMPA2—liver—type 2 diabetes mellitus	0.00423	0.0189	CbGeAlD
Lithium—GSK3B—liver—type 2 diabetes mellitus	0.00415	0.0185	CbGeAlD
Lithium—GSK3A—liver—type 2 diabetes mellitus	0.00361	0.0161	CbGeAlD
Lithium—Musculoskeletal discomfort—Glyburide—type 2 diabetes mellitus	0.000497	0.00143	CcSEcCtD
Lithium—Vertigo—Valsartan—type 2 diabetes mellitus	0.000496	0.00142	CcSEcCtD
Lithium—Flatulence—Metformin—type 2 diabetes mellitus	0.000495	0.00142	CcSEcCtD
Lithium—Syncope—Valsartan—type 2 diabetes mellitus	0.000495	0.00142	CcSEcCtD
Lithium—Confusional state—Gliclazide—type 2 diabetes mellitus	0.000494	0.00142	CcSEcCtD
Lithium—Dysgeusia—Metformin—type 2 diabetes mellitus	0.000492	0.00141	CcSEcCtD
Lithium—Feeling abnormal—Bromocriptine—type 2 diabetes mellitus	0.000492	0.00141	CcSEcCtD
Lithium—Vertigo—Orlistat—type 2 diabetes mellitus	0.00049	0.0014	CcSEcCtD
Lithium—Gastrointestinal pain—Bromocriptine—type 2 diabetes mellitus	0.000488	0.0014	CcSEcCtD
Lithium—Asthenia—Pioglitazone—type 2 diabetes mellitus	0.000488	0.0014	CcSEcCtD
Lithium—Arrhythmia—Irbesartan—type 2 diabetes mellitus	0.000487	0.0014	CcSEcCtD
Lithium—Diarrhoea—Glipizide—type 2 diabetes mellitus	0.000485	0.00139	CcSEcCtD
Lithium—Loss of consciousness—Valsartan—type 2 diabetes mellitus	0.000485	0.00139	CcSEcCtD
Lithium—Nausea—Rosiglitazone—type 2 diabetes mellitus	0.000481	0.00138	CcSEcCtD
Lithium—Dyspepsia—Glyburide—type 2 diabetes mellitus	0.000481	0.00138	CcSEcCtD
Lithium—Tinnitus—Losartan—type 2 diabetes mellitus	0.000478	0.00137	CcSEcCtD
Lithium—Asthenia—Glimepiride—type 2 diabetes mellitus	0.000475	0.00136	CcSEcCtD
Lithium—Decreased appetite—Glyburide—type 2 diabetes mellitus	0.000475	0.00136	CcSEcCtD
Lithium—Vision blurred—Metformin—type 2 diabetes mellitus	0.000474	0.00136	CcSEcCtD
Lithium—Asthenia—Sitagliptin—type 2 diabetes mellitus	0.000474	0.00136	CcSEcCtD
Lithium—Convulsion—Orlistat—type 2 diabetes mellitus	0.000473	0.00135	CcSEcCtD
Lithium—Abdominal pain—Bromocriptine—type 2 diabetes mellitus	0.000472	0.00135	CcSEcCtD
Lithium—Body temperature increased—Bromocriptine—type 2 diabetes mellitus	0.000472	0.00135	CcSEcCtD
Lithium—Tremor—Metformin—type 2 diabetes mellitus	0.000471	0.00135	CcSEcCtD
Lithium—Arthralgia—Valsartan—type 2 diabetes mellitus	0.00047	0.00135	CcSEcCtD
Lithium—Dizziness—Glipizide—type 2 diabetes mellitus	0.000469	0.00134	CcSEcCtD
Lithium—Flatulence—Irbesartan—type 2 diabetes mellitus	0.000467	0.00134	CcSEcCtD
Lithium—Diarrhoea—Pioglitazone—type 2 diabetes mellitus	0.000465	0.00133	CcSEcCtD
Lithium—Dysgeusia—Irbesartan—type 2 diabetes mellitus	0.000464	0.00133	CcSEcCtD
Lithium—Dry mouth—Valsartan—type 2 diabetes mellitus	0.00046	0.00132	CcSEcCtD
Lithium—Discomfort—Orlistat—type 2 diabetes mellitus	0.000459	0.00131	CcSEcCtD
Lithium—Hypotension—Gliclazide—type 2 diabetes mellitus	0.000458	0.00131	CcSEcCtD
Lithium—Arrhythmia—Losartan—type 2 diabetes mellitus	0.000458	0.00131	CcSEcCtD
Lithium—Dry mouth—Orlistat—type 2 diabetes mellitus	0.000454	0.0013	CcSEcCtD
Lithium—Alopecia—Losartan—type 2 diabetes mellitus	0.000453	0.0013	CcSEcCtD
Lithium—Diarrhoea—Glimepiride—type 2 diabetes mellitus	0.000453	0.0013	CcSEcCtD
Lithium—Diarrhoea—Sitagliptin—type 2 diabetes mellitus	0.000452	0.00129	CcSEcCtD
Lithium—Vomiting—Glipizide—type 2 diabetes mellitus	0.000451	0.00129	CcSEcCtD
Lithium—Syncope—Metformin—type 2 diabetes mellitus	0.000451	0.00129	CcSEcCtD
Lithium—Oedema—Valsartan—type 2 diabetes mellitus	0.00045	0.00129	CcSEcCtD
Lithium—Feeling abnormal—Glyburide—type 2 diabetes mellitus	0.00045	0.00129	CcSEcCtD
Lithium—Dizziness—Pioglitazone—type 2 diabetes mellitus	0.000449	0.00129	CcSEcCtD
Lithium—Rash—Glipizide—type 2 diabetes mellitus	0.000447	0.00128	CcSEcCtD
Lithium—Vision blurred—Irbesartan—type 2 diabetes mellitus	0.000447	0.00128	CcSEcCtD
Lithium—Dermatitis—Glipizide—type 2 diabetes mellitus	0.000447	0.00128	CcSEcCtD
Lithium—Musculoskeletal discomfort—Gliclazide—type 2 diabetes mellitus	0.000447	0.00128	CcSEcCtD
Lithium—Gastrointestinal pain—Glyburide—type 2 diabetes mellitus	0.000446	0.00128	CcSEcCtD
Lithium—Oedema—Orlistat—type 2 diabetes mellitus	0.000445	0.00128	CcSEcCtD
Lithium—Headache—Glipizide—type 2 diabetes mellitus	0.000444	0.00127	CcSEcCtD
Lithium—Tremor—Irbesartan—type 2 diabetes mellitus	0.000444	0.00127	CcSEcCtD
Lithium—Shock—Valsartan—type 2 diabetes mellitus	0.000443	0.00127	CcSEcCtD
Lithium—Loss of consciousness—Metformin—type 2 diabetes mellitus	0.000442	0.00127	CcSEcCtD
Lithium—Flatulence—Losartan—type 2 diabetes mellitus	0.00044	0.00126	CcSEcCtD
Lithium—Dizziness—Glimepiride—type 2 diabetes mellitus	0.000438	0.00125	CcSEcCtD
Lithium—Dysgeusia—Losartan—type 2 diabetes mellitus	0.000437	0.00125	CcSEcCtD
Lithium—Dizziness—Sitagliptin—type 2 diabetes mellitus	0.000436	0.00125	CcSEcCtD
Lithium—Agitation—Irbesartan—type 2 diabetes mellitus	0.000436	0.00125	CcSEcCtD
Lithium—Somnolence—Gliclazide—type 2 diabetes mellitus	0.000436	0.00125	CcSEcCtD
Lithium—Angioedema—Irbesartan—type 2 diabetes mellitus	0.000433	0.00124	CcSEcCtD
Lithium—Abdominal pain—Glyburide—type 2 diabetes mellitus	0.000432	0.00124	CcSEcCtD
Lithium—Dyspepsia—Gliclazide—type 2 diabetes mellitus	0.000432	0.00124	CcSEcCtD
Lithium—Anorexia—Valsartan—type 2 diabetes mellitus	0.000429	0.00123	CcSEcCtD
Lithium—Asthenia—Bromocriptine—type 2 diabetes mellitus	0.000429	0.00123	CcSEcCtD
Lithium—Vertigo—Irbesartan—type 2 diabetes mellitus	0.000426	0.00122	CcSEcCtD
Lithium—Headache—Pioglitazone—type 2 diabetes mellitus	0.000426	0.00122	CcSEcCtD
Lithium—Syncope—Irbesartan—type 2 diabetes mellitus	0.000425	0.00122	CcSEcCtD
Lithium—Discomfort—Metformin—type 2 diabetes mellitus	0.000423	0.00121	CcSEcCtD
Lithium—Fatigue—Gliclazide—type 2 diabetes mellitus	0.000423	0.00121	CcSEcCtD
Lithium—Nausea—Glipizide—type 2 diabetes mellitus	0.000421	0.00121	CcSEcCtD
Lithium—Vomiting—Glimepiride—type 2 diabetes mellitus	0.000421	0.00121	CcSEcCtD
Lithium—Hypotension—Valsartan—type 2 diabetes mellitus	0.000421	0.00121	CcSEcCtD
Lithium—Vision blurred—Losartan—type 2 diabetes mellitus	0.000421	0.00121	CcSEcCtD
Lithium—Vomiting—Sitagliptin—type 2 diabetes mellitus	0.00042	0.0012	CcSEcCtD
Lithium—Tremor—Losartan—type 2 diabetes mellitus	0.000418	0.0012	CcSEcCtD
Lithium—Rash—Glimepiride—type 2 diabetes mellitus	0.000417	0.0012	CcSEcCtD
Lithium—Dermatitis—Glimepiride—type 2 diabetes mellitus	0.000417	0.0012	CcSEcCtD
Lithium—Loss of consciousness—Irbesartan—type 2 diabetes mellitus	0.000417	0.00119	CcSEcCtD
Lithium—Rash—Sitagliptin—type 2 diabetes mellitus	0.000416	0.00119	CcSEcCtD
Lithium—Dermatitis—Sitagliptin—type 2 diabetes mellitus	0.000416	0.00119	CcSEcCtD
Lithium—Headache—Glimepiride—type 2 diabetes mellitus	0.000415	0.00119	CcSEcCtD
Lithium—Headache—Sitagliptin—type 2 diabetes mellitus	0.000413	0.00119	CcSEcCtD
Lithium—Musculoskeletal discomfort—Valsartan—type 2 diabetes mellitus	0.00041	0.00118	CcSEcCtD
Lithium—Agitation—Losartan—type 2 diabetes mellitus	0.00041	0.00118	CcSEcCtD
Lithium—Oedema—Metformin—type 2 diabetes mellitus	0.00041	0.00118	CcSEcCtD
Lithium—Tinnitus—Ramipril—type 2 diabetes mellitus	0.00041	0.00118	CcSEcCtD
Lithium—Diarrhoea—Bromocriptine—type 2 diabetes mellitus	0.000409	0.00117	CcSEcCtD
Lithium—Angioedema—Losartan—type 2 diabetes mellitus	0.000408	0.00117	CcSEcCtD
Lithium—Musculoskeletal discomfort—Orlistat—type 2 diabetes mellitus	0.000406	0.00116	CcSEcCtD
Lithium—Feeling abnormal—Gliclazide—type 2 diabetes mellitus	0.000404	0.00116	CcSEcCtD
Lithium—Arthralgia—Irbesartan—type 2 diabetes mellitus	0.000404	0.00116	CcSEcCtD
Lithium—Shock—Metformin—type 2 diabetes mellitus	0.000404	0.00116	CcSEcCtD
Lithium—Vertigo—Losartan—type 2 diabetes mellitus	0.000401	0.00115	CcSEcCtD
Lithium—Gastrointestinal pain—Gliclazide—type 2 diabetes mellitus	0.000401	0.00115	CcSEcCtD
Lithium—Somnolence—Valsartan—type 2 diabetes mellitus	0.0004	0.00115	CcSEcCtD
Lithium—Syncope—Losartan—type 2 diabetes mellitus	0.0004	0.00115	CcSEcCtD
Lithium—Discomfort—Irbesartan—type 2 diabetes mellitus	0.000399	0.00114	CcSEcCtD
Lithium—Dyspepsia—Valsartan—type 2 diabetes mellitus	0.000396	0.00114	CcSEcCtD
Lithium—Dizziness—Bromocriptine—type 2 diabetes mellitus	0.000395	0.00113	CcSEcCtD
Lithium—Dry mouth—Irbesartan—type 2 diabetes mellitus	0.000395	0.00113	CcSEcCtD
Lithium—Nausea—Glimepiride—type 2 diabetes mellitus	0.000393	0.00113	CcSEcCtD
Lithium—Arrhythmia—Ramipril—type 2 diabetes mellitus	0.000393	0.00113	CcSEcCtD
Lithium—Loss of consciousness—Losartan—type 2 diabetes mellitus	0.000392	0.00112	CcSEcCtD
Lithium—Nausea—Sitagliptin—type 2 diabetes mellitus	0.000392	0.00112	CcSEcCtD
Lithium—Dyspepsia—Orlistat—type 2 diabetes mellitus	0.000392	0.00112	CcSEcCtD
Lithium—Asthenia—Glyburide—type 2 diabetes mellitus	0.000392	0.00112	CcSEcCtD
Lithium—Decreased appetite—Valsartan—type 2 diabetes mellitus	0.000392	0.00112	CcSEcCtD
Lithium—Anorexia—Metformin—type 2 diabetes mellitus	0.000391	0.00112	CcSEcCtD
Lithium—Alopecia—Ramipril—type 2 diabetes mellitus	0.000389	0.00111	CcSEcCtD
Lithium—Fatigue—Valsartan—type 2 diabetes mellitus	0.000388	0.00111	CcSEcCtD
Lithium—Abdominal pain—Gliclazide—type 2 diabetes mellitus	0.000388	0.00111	CcSEcCtD
Lithium—Body temperature increased—Gliclazide—type 2 diabetes mellitus	0.000388	0.00111	CcSEcCtD
Lithium—Oedema—Irbesartan—type 2 diabetes mellitus	0.000387	0.00111	CcSEcCtD
Lithium—Decreased appetite—Orlistat—type 2 diabetes mellitus	0.000387	0.00111	CcSEcCtD
Lithium—Fatigue—Orlistat—type 2 diabetes mellitus	0.000384	0.0011	CcSEcCtD
Lithium—Hypotension—Metformin—type 2 diabetes mellitus	0.000383	0.0011	CcSEcCtD
Lithium—Shock—Irbesartan—type 2 diabetes mellitus	0.000381	0.00109	CcSEcCtD
Lithium—Arthralgia—Losartan—type 2 diabetes mellitus	0.00038	0.00109	CcSEcCtD
Lithium—Vomiting—Bromocriptine—type 2 diabetes mellitus	0.00038	0.00109	CcSEcCtD
Lithium—Rash—Bromocriptine—type 2 diabetes mellitus	0.000377	0.00108	CcSEcCtD
Lithium—Dermatitis—Bromocriptine—type 2 diabetes mellitus	0.000376	0.00108	CcSEcCtD
Lithium—Discomfort—Losartan—type 2 diabetes mellitus	0.000375	0.00108	CcSEcCtD
Lithium—Dysgeusia—Ramipril—type 2 diabetes mellitus	0.000375	0.00107	CcSEcCtD
Lithium—Headache—Bromocriptine—type 2 diabetes mellitus	0.000374	0.00107	CcSEcCtD
Lithium—Musculoskeletal discomfort—Metformin—type 2 diabetes mellitus	0.000374	0.00107	CcSEcCtD
Lithium—Diarrhoea—Glyburide—type 2 diabetes mellitus	0.000374	0.00107	CcSEcCtD
Lithium—Dry mouth—Losartan—type 2 diabetes mellitus	0.000372	0.00107	CcSEcCtD
Lithium—Anorexia—Irbesartan—type 2 diabetes mellitus	0.000369	0.00106	CcSEcCtD
Lithium—Gastrointestinal pain—Valsartan—type 2 diabetes mellitus	0.000368	0.00106	CcSEcCtD
Lithium—Confusional state—Losartan—type 2 diabetes mellitus	0.000367	0.00105	CcSEcCtD
Lithium—Feeling abnormal—Orlistat—type 2 diabetes mellitus	0.000367	0.00105	CcSEcCtD
Lithium—Somnolence—Metformin—type 2 diabetes mellitus	0.000365	0.00105	CcSEcCtD
Lithium—Oedema—Losartan—type 2 diabetes mellitus	0.000364	0.00104	CcSEcCtD
Lithium—Gastrointestinal pain—Orlistat—type 2 diabetes mellitus	0.000364	0.00104	CcSEcCtD
Lithium—Hypotension—Irbesartan—type 2 diabetes mellitus	0.000362	0.00104	CcSEcCtD
Lithium—Dyspepsia—Metformin—type 2 diabetes mellitus	0.000361	0.00103	CcSEcCtD
Lithium—Tremor—Ramipril—type 2 diabetes mellitus	0.000359	0.00103	CcSEcCtD
Lithium—Shock—Losartan—type 2 diabetes mellitus	0.000358	0.00103	CcSEcCtD
Lithium—Decreased appetite—Metformin—type 2 diabetes mellitus	0.000357	0.00102	CcSEcCtD
Lithium—Abdominal pain—Valsartan—type 2 diabetes mellitus	0.000356	0.00102	CcSEcCtD
Lithium—Nausea—Bromocriptine—type 2 diabetes mellitus	0.000355	0.00102	CcSEcCtD
Lithium—Fatigue—Metformin—type 2 diabetes mellitus	0.000354	0.00101	CcSEcCtD
Lithium—Musculoskeletal discomfort—Irbesartan—type 2 diabetes mellitus	0.000353	0.00101	CcSEcCtD
Lithium—Abdominal pain—Orlistat—type 2 diabetes mellitus	0.000352	0.00101	CcSEcCtD
Lithium—Body temperature increased—Orlistat—type 2 diabetes mellitus	0.000352	0.00101	CcSEcCtD
Lithium—Asthenia—Gliclazide—type 2 diabetes mellitus	0.000352	0.00101	CcSEcCtD
Lithium—Agitation—Ramipril—type 2 diabetes mellitus	0.000352	0.00101	CcSEcCtD
Lithium—Angioedema—Ramipril—type 2 diabetes mellitus	0.00035	0.001	CcSEcCtD
Lithium—Anorexia—Losartan—type 2 diabetes mellitus	0.000347	0.000995	CcSEcCtD
Lithium—Vomiting—Glyburide—type 2 diabetes mellitus	0.000347	0.000995	CcSEcCtD
Lithium—Rash—Glyburide—type 2 diabetes mellitus	0.000344	0.000987	CcSEcCtD
Lithium—Somnolence—Irbesartan—type 2 diabetes mellitus	0.000344	0.000986	CcSEcCtD
Lithium—Dermatitis—Glyburide—type 2 diabetes mellitus	0.000344	0.000986	CcSEcCtD
Lithium—Vertigo—Ramipril—type 2 diabetes mellitus	0.000344	0.000986	CcSEcCtD
Lithium—Syncope—Ramipril—type 2 diabetes mellitus	0.000343	0.000984	CcSEcCtD
Lithium—Headache—Glyburide—type 2 diabetes mellitus	0.000342	0.00098	CcSEcCtD
Lithium—Dyspepsia—Irbesartan—type 2 diabetes mellitus	0.000341	0.000977	CcSEcCtD
Lithium—Hypotension—Losartan—type 2 diabetes mellitus	0.00034	0.000976	CcSEcCtD
Lithium—Feeling abnormal—Metformin—type 2 diabetes mellitus	0.000338	0.000969	CcSEcCtD
Lithium—Decreased appetite—Irbesartan—type 2 diabetes mellitus	0.000336	0.000965	CcSEcCtD
Lithium—Loss of consciousness—Ramipril—type 2 diabetes mellitus	0.000336	0.000964	CcSEcCtD
Lithium—Diarrhoea—Gliclazide—type 2 diabetes mellitus	0.000335	0.000962	CcSEcCtD
Lithium—Gastrointestinal pain—Metformin—type 2 diabetes mellitus	0.000335	0.000961	CcSEcCtD
Lithium—Fatigue—Irbesartan—type 2 diabetes mellitus	0.000334	0.000957	CcSEcCtD
Lithium—Musculoskeletal discomfort—Losartan—type 2 diabetes mellitus	0.000332	0.000951	CcSEcCtD
Lithium—Convulsion—Ramipril—type 2 diabetes mellitus	0.000332	0.000951	CcSEcCtD
Lithium—Arthralgia—Ramipril—type 2 diabetes mellitus	0.000326	0.000934	CcSEcCtD
Lithium—Nausea—Glyburide—type 2 diabetes mellitus	0.000324	0.00093	CcSEcCtD
Lithium—Abdominal pain—Metformin—type 2 diabetes mellitus	0.000324	0.000929	CcSEcCtD
Lithium—Dizziness—Gliclazide—type 2 diabetes mellitus	0.000324	0.000929	CcSEcCtD
Lithium—Somnolence—Losartan—type 2 diabetes mellitus	0.000324	0.000928	CcSEcCtD
Lithium—Asthenia—Valsartan—type 2 diabetes mellitus	0.000323	0.000926	CcSEcCtD
Lithium—Discomfort—Ramipril—type 2 diabetes mellitus	0.000322	0.000923	CcSEcCtD
Lithium—Dyspepsia—Losartan—type 2 diabetes mellitus	0.000321	0.000919	CcSEcCtD
Lithium—Asthenia—Orlistat—type 2 diabetes mellitus	0.000319	0.000915	CcSEcCtD
Lithium—Feeling abnormal—Irbesartan—type 2 diabetes mellitus	0.000319	0.000914	CcSEcCtD
Lithium—Dry mouth—Ramipril—type 2 diabetes mellitus	0.000319	0.000913	CcSEcCtD
Lithium—Decreased appetite—Losartan—type 2 diabetes mellitus	0.000317	0.000908	CcSEcCtD
Lithium—Gastrointestinal pain—Irbesartan—type 2 diabetes mellitus	0.000317	0.000907	CcSEcCtD
Lithium—Confusional state—Ramipril—type 2 diabetes mellitus	0.000315	0.000903	CcSEcCtD
Lithium—Fatigue—Losartan—type 2 diabetes mellitus	0.000314	0.0009	CcSEcCtD
Lithium—Oedema—Ramipril—type 2 diabetes mellitus	0.000312	0.000895	CcSEcCtD
Lithium—Vomiting—Gliclazide—type 2 diabetes mellitus	0.000312	0.000894	CcSEcCtD
Lithium—Rash—Gliclazide—type 2 diabetes mellitus	0.000309	0.000886	CcSEcCtD
Lithium—Dermatitis—Gliclazide—type 2 diabetes mellitus	0.000309	0.000885	CcSEcCtD
Lithium—Diarrhoea—Valsartan—type 2 diabetes mellitus	0.000308	0.000883	CcSEcCtD
Lithium—Shock—Ramipril—type 2 diabetes mellitus	0.000307	0.000881	CcSEcCtD
Lithium—Headache—Gliclazide—type 2 diabetes mellitus	0.000307	0.00088	CcSEcCtD
Lithium—Abdominal pain—Irbesartan—type 2 diabetes mellitus	0.000306	0.000877	CcSEcCtD
Lithium—Body temperature increased—Irbesartan—type 2 diabetes mellitus	0.000306	0.000877	CcSEcCtD
Lithium—Diarrhoea—Orlistat—type 2 diabetes mellitus	0.000305	0.000873	CcSEcCtD
Lithium—Feeling abnormal—Losartan—type 2 diabetes mellitus	0.0003	0.00086	CcSEcCtD
Lithium—Gastrointestinal pain—Losartan—type 2 diabetes mellitus	0.000298	0.000854	CcSEcCtD
Lithium—Dizziness—Valsartan—type 2 diabetes mellitus	0.000298	0.000854	CcSEcCtD
Lithium—Anorexia—Ramipril—type 2 diabetes mellitus	0.000298	0.000853	CcSEcCtD
Lithium—Dizziness—Orlistat—type 2 diabetes mellitus	0.000294	0.000844	CcSEcCtD
Lithium—Asthenia—Metformin—type 2 diabetes mellitus	0.000294	0.000844	CcSEcCtD
Lithium—Hypotension—Ramipril—type 2 diabetes mellitus	0.000292	0.000837	CcSEcCtD
Lithium—Nausea—Gliclazide—type 2 diabetes mellitus	0.000291	0.000835	CcSEcCtD
Lithium—Abdominal pain—Losartan—type 2 diabetes mellitus	0.000288	0.000825	CcSEcCtD
Lithium—Body temperature increased—Losartan—type 2 diabetes mellitus	0.000288	0.000825	CcSEcCtD
Lithium—Vomiting—Valsartan—type 2 diabetes mellitus	0.000286	0.000821	CcSEcCtD
Lithium—Musculoskeletal discomfort—Ramipril—type 2 diabetes mellitus	0.000285	0.000816	CcSEcCtD
Lithium—Rash—Valsartan—type 2 diabetes mellitus	0.000284	0.000814	CcSEcCtD
Lithium—Dermatitis—Valsartan—type 2 diabetes mellitus	0.000284	0.000813	CcSEcCtD
Lithium—Vomiting—Orlistat—type 2 diabetes mellitus	0.000283	0.000811	CcSEcCtD
Lithium—Headache—Valsartan—type 2 diabetes mellitus	0.000282	0.000809	CcSEcCtD
Lithium—Diarrhoea—Metformin—type 2 diabetes mellitus	0.000281	0.000804	CcSEcCtD
Lithium—Rash—Orlistat—type 2 diabetes mellitus	0.000281	0.000804	CcSEcCtD
Lithium—Dermatitis—Orlistat—type 2 diabetes mellitus	0.00028	0.000804	CcSEcCtD
Lithium—Headache—Orlistat—type 2 diabetes mellitus	0.000279	0.000799	CcSEcCtD
Lithium—Asthenia—Irbesartan—type 2 diabetes mellitus	0.000278	0.000796	CcSEcCtD
Lithium—Somnolence—Ramipril—type 2 diabetes mellitus	0.000278	0.000796	CcSEcCtD
Lithium—Dyspepsia—Ramipril—type 2 diabetes mellitus	0.000275	0.000788	CcSEcCtD
Lithium—Decreased appetite—Ramipril—type 2 diabetes mellitus	0.000272	0.000778	CcSEcCtD
Lithium—Dizziness—Metformin—type 2 diabetes mellitus	0.000271	0.000778	CcSEcCtD
Lithium—Fatigue—Ramipril—type 2 diabetes mellitus	0.000269	0.000772	CcSEcCtD
Lithium—Nausea—Valsartan—type 2 diabetes mellitus	0.000268	0.000767	CcSEcCtD
Lithium—Diarrhoea—Irbesartan—type 2 diabetes mellitus	0.000265	0.000759	CcSEcCtD
Lithium—Nausea—Orlistat—type 2 diabetes mellitus	0.000264	0.000758	CcSEcCtD
Lithium—Asthenia—Losartan—type 2 diabetes mellitus	0.000261	0.000749	CcSEcCtD
Lithium—Vomiting—Metformin—type 2 diabetes mellitus	0.000261	0.000748	CcSEcCtD
Lithium—Rash—Metformin—type 2 diabetes mellitus	0.000259	0.000741	CcSEcCtD
Lithium—Dermatitis—Metformin—type 2 diabetes mellitus	0.000258	0.000741	CcSEcCtD
Lithium—Feeling abnormal—Ramipril—type 2 diabetes mellitus	0.000257	0.000738	CcSEcCtD
Lithium—Headache—Metformin—type 2 diabetes mellitus	0.000257	0.000737	CcSEcCtD
Lithium—Dizziness—Irbesartan—type 2 diabetes mellitus	0.000256	0.000734	CcSEcCtD
Lithium—Gastrointestinal pain—Ramipril—type 2 diabetes mellitus	0.000255	0.000732	CcSEcCtD
Lithium—Diarrhoea—Losartan—type 2 diabetes mellitus	0.000249	0.000714	CcSEcCtD
Lithium—Abdominal pain—Ramipril—type 2 diabetes mellitus	0.000247	0.000708	CcSEcCtD
Lithium—Body temperature increased—Ramipril—type 2 diabetes mellitus	0.000247	0.000708	CcSEcCtD
Lithium—Vomiting—Irbesartan—type 2 diabetes mellitus	0.000246	0.000705	CcSEcCtD
Lithium—Rash—Irbesartan—type 2 diabetes mellitus	0.000244	0.0007	CcSEcCtD
Lithium—Dermatitis—Irbesartan—type 2 diabetes mellitus	0.000244	0.000699	CcSEcCtD
Lithium—Nausea—Metformin—type 2 diabetes mellitus	0.000244	0.000698	CcSEcCtD
Lithium—Headache—Irbesartan—type 2 diabetes mellitus	0.000243	0.000695	CcSEcCtD
Lithium—Dizziness—Losartan—type 2 diabetes mellitus	0.000241	0.000691	CcSEcCtD
Lithium—Vomiting—Losartan—type 2 diabetes mellitus	0.000232	0.000664	CcSEcCtD
Lithium—Nausea—Irbesartan—type 2 diabetes mellitus	0.00023	0.000659	CcSEcCtD
Lithium—Rash—Losartan—type 2 diabetes mellitus	0.00023	0.000658	CcSEcCtD
Lithium—Dermatitis—Losartan—type 2 diabetes mellitus	0.000229	0.000658	CcSEcCtD
Lithium—Headache—Losartan—type 2 diabetes mellitus	0.000228	0.000654	CcSEcCtD
Lithium—Asthenia—Ramipril—type 2 diabetes mellitus	0.000224	0.000642	CcSEcCtD
Lithium—Nausea—Losartan—type 2 diabetes mellitus	0.000216	0.00062	CcSEcCtD
Lithium—Diarrhoea—Ramipril—type 2 diabetes mellitus	0.000214	0.000613	CcSEcCtD
Lithium—Dizziness—Ramipril—type 2 diabetes mellitus	0.000207	0.000592	CcSEcCtD
Lithium—Vomiting—Ramipril—type 2 diabetes mellitus	0.000199	0.000569	CcSEcCtD
Lithium—Rash—Ramipril—type 2 diabetes mellitus	0.000197	0.000565	CcSEcCtD
Lithium—Dermatitis—Ramipril—type 2 diabetes mellitus	0.000197	0.000564	CcSEcCtD
Lithium—Headache—Ramipril—type 2 diabetes mellitus	0.000196	0.000561	CcSEcCtD
Lithium—Nausea—Ramipril—type 2 diabetes mellitus	0.000186	0.000532	CcSEcCtD
Lithium—GSK3A—Signaling Pathways—GHRL—type 2 diabetes mellitus	5.99e-05	0.00014	CbGpPWpGaD
Lithium—GSK3A—Immune System—C3—type 2 diabetes mellitus	5.99e-05	0.00014	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—CASP8—type 2 diabetes mellitus	5.95e-05	0.000139	CbGpPWpGaD
Lithium—GSK3B—Disease—NOS1—type 2 diabetes mellitus	5.95e-05	0.000139	CbGpPWpGaD
Lithium—GSK3B—Focal Adhesion—AKT1—type 2 diabetes mellitus	5.92e-05	0.000139	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—CALCA—type 2 diabetes mellitus	5.92e-05	0.000139	CbGpPWpGaD
Lithium—GSK3B—Disease—TCF7L2—type 2 diabetes mellitus	5.88e-05	0.000138	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—RBP4—type 2 diabetes mellitus	5.84e-05	0.000137	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—GLP1R—type 2 diabetes mellitus	5.84e-05	0.000137	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—AKT2—type 2 diabetes mellitus	5.84e-05	0.000137	CbGpPWpGaD
Lithium—GSK3B—B Cell Activation—AKT1—type 2 diabetes mellitus	5.8e-05	0.000136	CbGpPWpGaD
Lithium—GSK3B—Disease—SLC2A4—type 2 diabetes mellitus	5.78e-05	0.000135	CbGpPWpGaD
Lithium—GSK3A—Signaling by NGF—AKT1—type 2 diabetes mellitus	5.78e-05	0.000135	CbGpPWpGaD
Lithium—GSK3A—Disease—PPP2CA—type 2 diabetes mellitus	5.76e-05	0.000135	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—CCKAR—type 2 diabetes mellitus	5.75e-05	0.000135	CbGpPWpGaD
Lithium—GSK3A—Immune System—BCL2L1—type 2 diabetes mellitus	5.73e-05	0.000134	CbGpPWpGaD
Lithium—GSK3A—Immune System—IRS2—type 2 diabetes mellitus	5.7e-05	0.000133	CbGpPWpGaD
Lithium—GSK3A—Immune System—CRP—type 2 diabetes mellitus	5.7e-05	0.000133	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—NFKB1—type 2 diabetes mellitus	5.69e-05	0.000133	CbGpPWpGaD
Lithium—GSK3A—Disease—CCR5—type 2 diabetes mellitus	5.66e-05	0.000132	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—RELA—type 2 diabetes mellitus	5.65e-05	0.000132	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—AKT2—type 2 diabetes mellitus	5.61e-05	0.000131	CbGpPWpGaD
Lithium—GSK3A—Immune System—CALM1—type 2 diabetes mellitus	5.6e-05	0.000131	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—TCF7L2—type 2 diabetes mellitus	5.58e-05	0.00013	CbGpPWpGaD
Lithium—GSK3B—NGF signalling via TRKA from the plasma membrane—AKT1—type 2 diabetes mellitus	5.55e-05	0.00013	CbGpPWpGaD
Lithium—GSK3A—Disease—MTHFR—type 2 diabetes mellitus	5.53e-05	0.000129	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—GCG—type 2 diabetes mellitus	5.48e-05	0.000128	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—PTPN1—type 2 diabetes mellitus	5.48e-05	0.000128	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—NFKB1—type 2 diabetes mellitus	5.47e-05	0.000128	CbGpPWpGaD
Lithium—GSK3B—Axon guidance—EGFR—type 2 diabetes mellitus	5.45e-05	0.000128	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—RASGRP1—type 2 diabetes mellitus	5.39e-05	0.000126	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—NOTCH2—type 2 diabetes mellitus	5.38e-05	0.000126	CbGpPWpGaD
Lithium—GSK3B—TCF dependent signaling in response to WNT—AKT1—type 2 diabetes mellitus	5.31e-05	0.000124	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—SRC—type 2 diabetes mellitus	5.31e-05	0.000124	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—PIK3R1—type 2 diabetes mellitus	5.3e-05	0.000124	CbGpPWpGaD
Lithium—GSK3A—Disease—HIF1A—type 2 diabetes mellitus	5.27e-05	0.000123	CbGpPWpGaD
Lithium—GSK3A—Disease—IRS2—type 2 diabetes mellitus	5.26e-05	0.000123	CbGpPWpGaD
Lithium—GSK3A—Immune System—PRKCB—type 2 diabetes mellitus	5.26e-05	0.000123	CbGpPWpGaD
Lithium—GSK3A—Immune System—ICAM1—type 2 diabetes mellitus	5.24e-05	0.000123	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—ATP2A2—type 2 diabetes mellitus	5.21e-05	0.000122	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—IAPP—type 2 diabetes mellitus	5.18e-05	0.000121	CbGpPWpGaD
Lithium—GSK3A—Disease—CALM1—type 2 diabetes mellitus	5.17e-05	0.000121	CbGpPWpGaD
Lithium—GSK3A—Disease—APOE—type 2 diabetes mellitus	5.15e-05	0.00012	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—INSR—type 2 diabetes mellitus	5.14e-05	0.00012	CbGpPWpGaD
Lithium—GSK3B—RNF mutants show enhanced WNT signaling and proliferation—AKT1—type 2 diabetes mellitus	5.14e-05	0.00012	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—BCL2—type 2 diabetes mellitus	5.1e-05	0.000119	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—SRC—type 2 diabetes mellitus	5.09e-05	0.000119	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—PIK3R1—type 2 diabetes mellitus	5.09e-05	0.000119	CbGpPWpGaD
Lithium—GSK3A—Disease—APOA1—type 2 diabetes mellitus	5.09e-05	0.000119	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—TRPC6—type 2 diabetes mellitus	5.05e-05	0.000118	CbGpPWpGaD
Lithium—GSK3B—Disease—TGFBR2—type 2 diabetes mellitus	5.03e-05	0.000118	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—AGTR2—type 2 diabetes mellitus	5.02e-05	0.000118	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—RELA—type 2 diabetes mellitus	4.99e-05	0.000117	CbGpPWpGaD
Lithium—GSK3A—Immune System—IRS1—type 2 diabetes mellitus	4.97e-05	0.000116	CbGpPWpGaD
Lithium—GSK3B—Cellular responses to stress—IL6—type 2 diabetes mellitus	4.94e-05	0.000116	CbGpPWpGaD
Lithium—GSK3B—Disease—CDKN2B—type 2 diabetes mellitus	4.87e-05	0.000114	CbGpPWpGaD
Lithium—GSK3B—Immune System—AGER—type 2 diabetes mellitus	4.83e-05	0.000113	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—MMP9—type 2 diabetes mellitus	4.81e-05	0.000113	CbGpPWpGaD
Lithium—GSK3B—Immune System—ADCY5—type 2 diabetes mellitus	4.81e-05	0.000113	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—EDNRB—type 2 diabetes mellitus	4.81e-05	0.000113	CbGpPWpGaD
Lithium—GSK3A—Disease—NOS2—type 2 diabetes mellitus	4.8e-05	0.000112	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—RELA—type 2 diabetes mellitus	4.79e-05	0.000112	CbGpPWpGaD
Lithium—GSK3B—Signaling by WNT in cancer—AKT1—type 2 diabetes mellitus	4.77e-05	0.000112	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—TGFBR2—type 2 diabetes mellitus	4.77e-05	0.000112	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—NFKB1—type 2 diabetes mellitus	4.76e-05	0.000111	CbGpPWpGaD
Lithium—GSK3B—Disease—APOB—type 2 diabetes mellitus	4.75e-05	0.000111	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—GNB3—type 2 diabetes mellitus	4.72e-05	0.000111	CbGpPWpGaD
Lithium—GSK3A—Immune System—CASP8—type 2 diabetes mellitus	4.69e-05	0.00011	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—PSMD6—type 2 diabetes mellitus	4.67e-05	0.000109	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—HTR2C—type 2 diabetes mellitus	4.67e-05	0.000109	CbGpPWpGaD
Lithium—GSK3B—Immune System—CD36—type 2 diabetes mellitus	4.67e-05	0.000109	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—MMP3—type 2 diabetes mellitus	4.66e-05	0.000109	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—AVP—type 2 diabetes mellitus	4.66e-05	0.000109	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—EGFR—type 2 diabetes mellitus	4.65e-05	0.000109	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—IGF2—type 2 diabetes mellitus	4.64e-05	0.000109	CbGpPWpGaD
Lithium—GSK3B—Signaling by NGF—IL6—type 2 diabetes mellitus	4.63e-05	0.000108	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—CDKN2B—type 2 diabetes mellitus	4.62e-05	0.000108	CbGpPWpGaD
Lithium—GSK3B—Immune System—PPP2CA—type 2 diabetes mellitus	4.61e-05	0.000108	CbGpPWpGaD
Lithium—GSK3A—Immune System—AKT2—type 2 diabetes mellitus	4.6e-05	0.000108	CbGpPWpGaD
Lithium—GSK3A—Disease—IRS1—type 2 diabetes mellitus	4.59e-05	0.000107	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—EDNRA—type 2 diabetes mellitus	4.54e-05	0.000106	CbGpPWpGaD
Lithium—GSK3B—Disease—LPL—type 2 diabetes mellitus	4.54e-05	0.000106	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—CYBA—type 2 diabetes mellitus	4.52e-05	0.000106	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—APOB—type 2 diabetes mellitus	4.5e-05	0.000105	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—IGF1R—type 2 diabetes mellitus	4.49e-05	0.000105	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—EGFR—type 2 diabetes mellitus	4.47e-05	0.000105	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—ADRA2A—type 2 diabetes mellitus	4.45e-05	0.000104	CbGpPWpGaD
Lithium—GSK3B—Disease—ADCY5—type 2 diabetes mellitus	4.44e-05	0.000104	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—SRC—type 2 diabetes mellitus	4.44e-05	0.000104	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—EDN1—type 2 diabetes mellitus	4.43e-05	0.000104	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—GHRL—type 2 diabetes mellitus	4.43e-05	0.000104	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—PLAT—type 2 diabetes mellitus	4.43e-05	0.000104	CbGpPWpGaD
Lithium—GSK3B—Immune System—C3—type 2 diabetes mellitus	4.43e-05	0.000104	CbGpPWpGaD
Lithium—IMPA2—Metabolism—AKT1—type 2 diabetes mellitus	4.43e-05	0.000104	CbGpPWpGaD
Lithium—GSK3A—Disease—INS—type 2 diabetes mellitus	4.4e-05	0.000103	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—CALCA—type 2 diabetes mellitus	4.37e-05	0.000102	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—VEGFA—type 2 diabetes mellitus	4.32e-05	0.000101	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—LPL—type 2 diabetes mellitus	4.3e-05	0.000101	CbGpPWpGaD
Lithium—GSK3B—Signaling by NGF—AKT1—type 2 diabetes mellitus	4.27e-05	0.0001	CbGpPWpGaD
Lithium—GSK3B—Disease—PPP2CA—type 2 diabetes mellitus	4.26e-05	9.97e-05	CbGpPWpGaD
Lithium—GSK3A—Disease—AKT2—type 2 diabetes mellitus	4.25e-05	9.95e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—BCL2L1—type 2 diabetes mellitus	4.24e-05	9.92e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—ADCY5—type 2 diabetes mellitus	4.21e-05	9.85e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—IRS2—type 2 diabetes mellitus	4.21e-05	9.85e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—CRP—type 2 diabetes mellitus	4.21e-05	9.85e-05	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—NFKB1—type 2 diabetes mellitus	4.21e-05	9.85e-05	CbGpPWpGaD
Lithium—GSK3B—Axon guidance—IL6—type 2 diabetes mellitus	4.19e-05	9.81e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—CCR5—type 2 diabetes mellitus	4.18e-05	9.79e-05	CbGpPWpGaD
Lithium—GSK3A—Immune System—PIK3R1—type 2 diabetes mellitus	4.18e-05	9.78e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—CALM1—type 2 diabetes mellitus	4.13e-05	9.68e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—TCF7L2—type 2 diabetes mellitus	4.12e-05	9.64e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—MTHFR—type 2 diabetes mellitus	4.09e-05	9.56e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—PTPN1—type 2 diabetes mellitus	4.05e-05	9.48e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—GCG—type 2 diabetes mellitus	4.05e-05	9.48e-05	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—NFKB1—type 2 diabetes mellitus	4.04e-05	9.46e-05	CbGpPWpGaD
Lithium—GSK3A—Disease—SERPINE1—type 2 diabetes mellitus	4.04e-05	9.46e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—PPP2CA—type 2 diabetes mellitus	4.04e-05	9.44e-05	CbGpPWpGaD
Lithium—GSK3A—Immune System—BCL2—type 2 diabetes mellitus	4.02e-05	9.41e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—RASGRP1—type 2 diabetes mellitus	3.98e-05	9.33e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—NOTCH2—type 2 diabetes mellitus	3.97e-05	9.3e-05	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—TGFB1—type 2 diabetes mellitus	3.97e-05	9.29e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—CCR5—type 2 diabetes mellitus	3.96e-05	9.27e-05	CbGpPWpGaD
Lithium—IMPA1—Metabolism—AKT1—type 2 diabetes mellitus	3.94e-05	9.23e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling by Wnt—AKT1—type 2 diabetes mellitus	3.93e-05	9.21e-05	CbGpPWpGaD
Lithium—GSK3A—Immune System—RELA—type 2 diabetes mellitus	3.93e-05	9.2e-05	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—SRC—type 2 diabetes mellitus	3.92e-05	9.18e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—HIF1A—type 2 diabetes mellitus	3.9e-05	9.12e-05	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—EGFR—type 2 diabetes mellitus	3.89e-05	9.11e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—IRS2—type 2 diabetes mellitus	3.89e-05	9.1e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—PRKCB—type 2 diabetes mellitus	3.89e-05	9.09e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—C3—type 2 diabetes mellitus	3.87e-05	9.06e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—ICAM1—type 2 diabetes mellitus	3.87e-05	9.06e-05	CbGpPWpGaD
Lithium—GSK3A—Disease—NOS3—type 2 diabetes mellitus	3.86e-05	9.03e-05	CbGpPWpGaD
Lithium—GSK3A—Disease—PIK3R1—type 2 diabetes mellitus	3.86e-05	9.03e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—CALM1—type 2 diabetes mellitus	3.82e-05	8.94e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—APOE—type 2 diabetes mellitus	3.8e-05	8.9e-05	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—SRC—type 2 diabetes mellitus	3.76e-05	8.81e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—APOA1—type 2 diabetes mellitus	3.76e-05	8.8e-05	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—TNF—type 2 diabetes mellitus	3.71e-05	8.67e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—HIF1A—type 2 diabetes mellitus	3.69e-05	8.64e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—IRS2—type 2 diabetes mellitus	3.68e-05	8.62e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—AGT—type 2 diabetes mellitus	3.68e-05	8.61e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—IRS1—type 2 diabetes mellitus	3.68e-05	8.6e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—CALM1—type 2 diabetes mellitus	3.62e-05	8.47e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—APOE—type 2 diabetes mellitus	3.61e-05	8.44e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—LEP—type 2 diabetes mellitus	3.61e-05	8.44e-05	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—IL6—type 2 diabetes mellitus	3.57e-05	8.36e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—APOA1—type 2 diabetes mellitus	3.56e-05	8.34e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—NOS2—type 2 diabetes mellitus	3.54e-05	8.3e-05	CbGpPWpGaD
Lithium—GSK3A—Disease—PTGS2—type 2 diabetes mellitus	3.53e-05	8.26e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—TGFBR2—type 2 diabetes mellitus	3.52e-05	8.25e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—GNB3—type 2 diabetes mellitus	3.49e-05	8.17e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—CASP8—type 2 diabetes mellitus	3.46e-05	8.11e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—MMP3—type 2 diabetes mellitus	3.44e-05	8.06e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—AVP—type 2 diabetes mellitus	3.44e-05	8.06e-05	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—EGFR—type 2 diabetes mellitus	3.44e-05	8.04e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—IGF2—type 2 diabetes mellitus	3.43e-05	8.02e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—CDKN2B—type 2 diabetes mellitus	3.41e-05	7.99e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—AKT2—type 2 diabetes mellitus	3.4e-05	7.96e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—PRKCB—type 2 diabetes mellitus	3.4e-05	7.96e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—IRS1—type 2 diabetes mellitus	3.39e-05	7.94e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—APOB—type 2 diabetes mellitus	3.33e-05	7.79e-05	CbGpPWpGaD
Lithium—GSK3A—Immune System—NFKB1—type 2 diabetes mellitus	3.32e-05	7.76e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—IGF1R—type 2 diabetes mellitus	3.31e-05	7.76e-05	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—EGFR—type 2 diabetes mellitus	3.3e-05	7.72e-05	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—AKT1—type 2 diabetes mellitus	3.3e-05	7.72e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—EDN1—type 2 diabetes mellitus	3.28e-05	7.67e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—INS—type 2 diabetes mellitus	3.25e-05	7.61e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—IRS1—type 2 diabetes mellitus	3.22e-05	7.53e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—LPL—type 2 diabetes mellitus	3.18e-05	7.44e-05	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—AKT1—type 2 diabetes mellitus	3.17e-05	7.41e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—AKT2—type 2 diabetes mellitus	3.14e-05	7.35e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—ADCY5—type 2 diabetes mellitus	3.11e-05	7.28e-05	CbGpPWpGaD
Lithium—GSK3A—Immune System—SRC—type 2 diabetes mellitus	3.09e-05	7.23e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—PIK3R1—type 2 diabetes mellitus	3.09e-05	7.22e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—INS—type 2 diabetes mellitus	3.08e-05	7.21e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—CCL2—type 2 diabetes mellitus	3.03e-05	7.09e-05	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—IL6—type 2 diabetes mellitus	2.99e-05	7e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—SERPINE1—type 2 diabetes mellitus	2.99e-05	6.99e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—PPP2CA—type 2 diabetes mellitus	2.98e-05	6.98e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—IGF1—type 2 diabetes mellitus	2.98e-05	6.97e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—AKT2—type 2 diabetes mellitus	2.98e-05	6.97e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—BCL2—type 2 diabetes mellitus	2.97e-05	6.96e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—CCR5—type 2 diabetes mellitus	2.93e-05	6.85e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—RELA—type 2 diabetes mellitus	2.91e-05	6.8e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—C3—type 2 diabetes mellitus	2.86e-05	6.7e-05	CbGpPWpGaD
Lithium—GSK3A—Disease—SRC—type 2 diabetes mellitus	2.85e-05	6.68e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—NOS3—type 2 diabetes mellitus	2.85e-05	6.67e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—PIK3R1—type 2 diabetes mellitus	2.85e-05	6.67e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	2.83e-05	6.62e-05	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—AKT1—type 2 diabetes mellitus	2.76e-05	6.46e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—HIF1A—type 2 diabetes mellitus	2.73e-05	6.39e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—IRS2—type 2 diabetes mellitus	2.72e-05	6.37e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—AGT—type 2 diabetes mellitus	2.72e-05	6.36e-05	CbGpPWpGaD
Lithium—GSK3A—Immune System—EGFR—type 2 diabetes mellitus	2.71e-05	6.34e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—NOS3—type 2 diabetes mellitus	2.7e-05	6.32e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	2.7e-05	6.32e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—CALM1—type 2 diabetes mellitus	2.67e-05	6.26e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—APOE—type 2 diabetes mellitus	2.66e-05	6.24e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—LEP—type 2 diabetes mellitus	2.66e-05	6.24e-05	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—IL6—type 2 diabetes mellitus	2.64e-05	6.18e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—APOA1—type 2 diabetes mellitus	2.63e-05	6.16e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—PTGS2—type 2 diabetes mellitus	2.61e-05	6.1e-05	CbGpPWpGaD
Lithium—GSK3A—Disease—TGFB1—type 2 diabetes mellitus	2.55e-05	5.97e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—RELA—type 2 diabetes mellitus	2.54e-05	5.95e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—PRKCB—type 2 diabetes mellitus	2.51e-05	5.88e-05	CbGpPWpGaD
Lithium—GSK3A—Disease—EGFR—type 2 diabetes mellitus	2.5e-05	5.85e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—NFKB1—type 2 diabetes mellitus	2.45e-05	5.74e-05	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—AKT1—type 2 diabetes mellitus	2.44e-05	5.7e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—IRS1—type 2 diabetes mellitus	2.38e-05	5.56e-05	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—AKT1—type 2 diabetes mellitus	2.34e-05	5.48e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—CASP3—type 2 diabetes mellitus	2.29e-05	5.37e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—SRC—type 2 diabetes mellitus	2.28e-05	5.34e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—INS—type 2 diabetes mellitus	2.28e-05	5.33e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—CCL2—type 2 diabetes mellitus	2.24e-05	5.24e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—IGF1—type 2 diabetes mellitus	2.2e-05	5.15e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—AKT2—type 2 diabetes mellitus	2.2e-05	5.15e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—MMP9—type 2 diabetes mellitus	2.17e-05	5.07e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—NFKB1—type 2 diabetes mellitus	2.14e-05	5.02e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—SRC—type 2 diabetes mellitus	2.11e-05	4.93e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	2.09e-05	4.89e-05	CbGpPWpGaD
Lithium—GSK3A—Immune System—IL6—type 2 diabetes mellitus	2.08e-05	4.87e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—EGFR—type 2 diabetes mellitus	2e-05	4.68e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—SRC—type 2 diabetes mellitus	2e-05	4.68e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—NOS3—type 2 diabetes mellitus	2e-05	4.67e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	2e-05	4.67e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—VEGFA—type 2 diabetes mellitus	1.95e-05	4.55e-05	CbGpPWpGaD
Lithium—GSK3A—Disease—IL6—type 2 diabetes mellitus	1.92e-05	4.5e-05	CbGpPWpGaD
Lithium—GSK3A—Immune System—AKT1—type 2 diabetes mellitus	1.92e-05	4.49e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—TGFB1—type 2 diabetes mellitus	1.88e-05	4.41e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—RELA—type 2 diabetes mellitus	1.88e-05	4.4e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—EGFR—type 2 diabetes mellitus	1.85e-05	4.32e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—TGFB1—type 2 diabetes mellitus	1.79e-05	4.18e-05	CbGpPWpGaD
Lithium—GSK3A—Disease—AKT1—type 2 diabetes mellitus	1.77e-05	4.15e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—EGFR—type 2 diabetes mellitus	1.75e-05	4.1e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—CASP3—type 2 diabetes mellitus	1.69e-05	3.97e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—MMP9—type 2 diabetes mellitus	1.6e-05	3.75e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—NFKB1—type 2 diabetes mellitus	1.58e-05	3.71e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—IL6—type 2 diabetes mellitus	1.54e-05	3.6e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—SRC—type 2 diabetes mellitus	1.48e-05	3.46e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—VEGFA—type 2 diabetes mellitus	1.44e-05	3.37e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—IL6—type 2 diabetes mellitus	1.42e-05	3.32e-05	CbGpPWpGaD
Lithium—GSK3B—Immune System—AKT1—type 2 diabetes mellitus	1.42e-05	3.32e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—IL6—type 2 diabetes mellitus	1.35e-05	3.15e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—TGFB1—type 2 diabetes mellitus	1.32e-05	3.09e-05	CbGpPWpGaD
Lithium—GSK3B—Disease—AKT1—type 2 diabetes mellitus	1.31e-05	3.07e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—EGFR—type 2 diabetes mellitus	1.29e-05	3.03e-05	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—AKT1—type 2 diabetes mellitus	1.24e-05	2.91e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—IL6—type 2 diabetes mellitus	9.94e-06	2.33e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—AKT1—type 2 diabetes mellitus	9.17e-06	2.15e-05	CbGpPWpGaD
